Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs 22nd Century Group Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $78.99, while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). Which is the better fit depends on your goals.
| IEMG | XXII | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $86.00 | $1.07K |
52-Week Low | $59.90 | $3.90 |
Market Cap | — | $1.49M |
Enterprise Value | — | -$6.74M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $77.21, up 0.3% with a bearish technical signal from moving averages and oscillators. The ETF shows strong recent performance with 35% gains over the past year, driven by emerging market inflows and AI-focused technology exposure. Recent news highlights record capital flows into emerging markets and IEMG's 40% technology weighting, though some analysts caution about elevated volatility and concentration risks.
The outlook remains mixed with attractive emerging market valuations and growth opportunities balanced against geopolitical risks and market volatility. Key catalysts include continued AI-driven technology performance and emerging market economic growth, while risks involve US-China tensions and potential market corrections given the ETF's recent strong run.
XXII trades at $4.32, down 0.23% with bearish technical signals. The company shows negative profitability with -65.76% net income margin and -130.19% ROE, though valuation ratios appear low with P/S of 0.03. Recent corporate actions include a 20:1 reverse stock split in June 2026. The company is expanding VLN product distribution in key markets including California and New York, supported by positive FDA regulatory developments.
While analyst consensus is 75% buy-rated, fundamental challenges persist with consistent revenue declines and negative cash flow from operations. Investment opportunity lies in successful VLN brand expansion and regulatory approvals, but risks include ongoing losses, competitive tobacco market pressures, and execution uncertainty in scaling reduced-nicotine products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
